Semin Respir Crit Care Med 2018; 39(04): 459-464
DOI: 10.1055/s-0038-1673387
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy

Alexandre Karras
1   Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique- Hôpitaux de Paris, Paris France
2   Faculté de Médecine, Université Paris Descartes, Paris, France
› Author Affiliations
Further Information

Publication History

Publication Date:
07 November 2018 (online)

Abstract

Microscopic polyangiitis (MPA) is one of the main clinical presentations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Although the disease is defined by clinical and pathological criteria, the anti-myeloperoxidase (MPO) specificity of ANCAs is observed in almost 80% of MPA patients. The direct pathogenic role of anti-MPO antibodies has been proven in animal models, in which the disease was transmitted by transfer of anti-MPO antibodies or anti-MPO–specific splenocytes. The most frequently affected organs in this disease are the kidneys and the lungs. Necrotizing and crescentic glomerulonephritis can be revealed by rapidly progressive renal failure, but kidney injury can be more slowly progressive and lead to end-stage renal disease without major extrarenal manifestations. The most frequent pulmonary manifestation is diffuse alveolar hemorrhage, but some patients may present with chronic interstitial fibrosis leading to respiratory failure. General signs such as fever and weight loss, muscular and articular symptoms, peripheral neuropathy, and cutaneous involvement may also reveal the disease. Although the relapse rate is quite low after induction of remission, 5-year mortality is 25%, with even higher mortality rates in older patients (> 65 years old), or those with significant kidney dysfunction. Iatrogenic causes (particularly infections) are an important cause of deaths in these vulnerable patients. Future studies are warranted to determine the optimal maintenance immunosuppressive regimen to minimize side effects of immunosuppression.

 
  • References

  • 1 Jennette JC, Falk RJ, Bacon PA. , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 (01) 1-11
  • 2 Watts R, Lane S, Hanslik T. , et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66 (02) 222-227
  • 3 Abdulkader R, Lane SE, Scott DGI, Watts RA. Classification of vasculitis: EMA classification using CHCC 2012 definitions. Ann Rheum Dis 2013; 72 (11) 1888-8
  • 4 Mahr A, Katsahian S, Varet H. , et al; French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS). Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013; 72 (06) 1003-1010
  • 5 Miloslavsky EM, Lu N, Unizony S. , et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener's): distinct patient subsets. Arthritis Rheumatol 2016; 68 (12) 2945-2952
  • 6 Schirmer JH, Wright MN, Herrmann K. , et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center. Arthritis Rheumatol 2016; 68 (12) 2953-2963
  • 7 Comarmond C, Pagnoux C, Khellaf M. , et al; French Vasculitis Study Group. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65 (01) 270-281
  • 8 Durel C-A, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken) 2016; 68 (03) 374-387
  • 9 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51 (01) 92-99
  • 10 Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007; 46 (08) 1329-1337
  • 11 Scott DGI, Watts RA. Epidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol 2013; 17 (05) 607-610
  • 12 Watts RA, Mooney J, Skinner J, Scott DGI, Macgregor AJ. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology (Oxford) 2012; 51 (05) 926-931
  • 13 Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49 (03) 388-393
  • 14 Watts RA, Lane SE, Scott DG. , et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60 (12) 1156-1157
  • 15 Watts RA, Scott DGI. ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately. Rheumatology (Oxford) 2012; 51 (12) 2115-2117
  • 16 Fujimoto S, Watts RA, Kobayashi S. , et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011; 50 (10) 1916-1920
  • 17 Guillevin L, Durand-Gasselin B, Cevallos R. , et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42 (03) 421-430
  • 18 Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients. Rheumatology (Oxford) 2005; 44 (04) 495-501
  • 19 Terrier B, Saadoun D, Sène D. , et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009; 68 (10) 1564-1571
  • 20 Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45 (04) 758-761
  • 21 Land J, Rutgers A, Kallenberg CG. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol Dial Transplant 2014; 29 (04) 739-745
  • 22 Xiao H, Heeringa P, Hu P. , et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110 (07) 955-963
  • 23 Guilpain P, Servettaz A, Goulvestre C. , et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007; 56 (07) 2455-2463
  • 24 Nakazawa D, Shida H, Tomaru U. , et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol 2014; 25 (05) 990-997
  • 25 Kessenbrock K, Krumbholz M, Schönermarck U. , et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15 (06) 623-625
  • 26 O'Sullivan KM, Lo CY, Summers SA. , et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney Int 2015; 88 (05) 1030-1046
  • 27 Lyons PA, Rayner TF, Trivedi S. , et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367 (03) 214-223
  • 28 Kain R, Exner M, Brandes R. , et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14 (10) 1088-1096
  • 29 Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RJ. ; Glomerular Disease Collaborative Network. Silica exposure in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and lupus nephritis. J Am Soc Nephrol 2001; 12 (01) 134-142
  • 30 Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev 2010; 9 (12) 812-819
  • 31 Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?. Ann Rheum Dis 2013; 72 (08) 1273-1279
  • 32 Lee T, Gasim A, Derebail VK. , et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 2014; 9 (05) 905-913
  • 33 Hauer HA, Bajema IM, Van Houwelingen HC. , et al; European Vasculitis Study Group (EUVAS). Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62 (05) 1732-1742
  • 34 Berden AE, Ferrario F, Hagen EC. , et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21 (10) 1628-1636
  • 35 Hilhorst M, Wilde B, van Breda Vriesman P, van Paassen P, Cohen Tervaert JW. ; Limburg Renal Registry. Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 2013; 24 (09) 1371-1375
  • 36 Ford SL, Polkinghorne KR, Longano A. , et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis 2014; 63 (02) 227-235
  • 37 Quintana LF, Peréz NS, De Sousa E. , et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2014; 29 (09) 1764-1769
  • 38 Comarmond C, Crestani B, Tazi A. , et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93 (24) 340-349
  • 39 Tzelepis GE, Kokosi M, Tzioufas A. , et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36 (01) 116-121
  • 40 Alba MA, Flores-Suárez LF, Henderson AG. , et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev 2017; 16 (07) 722-729
  • 41 Zhang W, Zhou G, Shi Q, Zhang X, Zeng X-F, Zhang F-C. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27 (01) (Suppl. 52) S65-S69
  • 42 Suppiah R, Hadden RDM, Batra R. , et al; European Vasculitis Study Group. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2011; 50 (12) 2214-2222
  • 43 Kluger N, Pagnoux C, Guillevin L, Francès C. ; French Vasculitis Study Group. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol 2008; 159 (03) 615-620
  • 44 Kallenberg CGM. The diagnosis and classification of microscopic polyangiitis. J Autoimmun 2014; 48-49: 90-93
  • 45 Booth AD, Almond MK, Burns A. , et al; Pan-Thames Renal Research Group. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41 (04) 776-784
  • 46 Furuta S, Chaudhry AN, Hamano Y. , et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 2014; 41 (02) 325-333
  • 47 Mukhtyar C, Flossmann O, Hellmich B. , et al; European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67 (07) 1004-1010
  • 48 Little MA, Nightingale P, Verburgh CA. , et al; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69 (06) 1036-1043
  • 49 Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 2014; 41 (07) 1366-1373
  • 50 Flossmann O, Berden A, de Groot K. , et al; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70 (03) 488-494
  • 51 Pagnoux C, Hogan SL, Chin H. , et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58 (09) 2908-2918
  • 52 Yates M, Watts RA, Bajema IM. , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75 (09) 1583-1594
  • 53 Mukhtyar C, Guillevin L, Cid MC. , et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68 (03) 310-317
  • 54 Walsh M, Flossmann O, Berden A. , et al; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64 (02) 542-548
  • 55 Specks U, Merkel PA, Seo P. , et al; RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369 (05) 417-427
  • 56 Terrier B, Pagnoux C, Perrodeau É. , et al; French Vasculitis Study Group. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 2018; 77 (08) 1150-1156
  • 57 Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 2016; 12 (10) 570-579